Insulet Corp Files 8-K
Ticker: PODD · Form: 8-K · Filed: Dec 4, 2024 · CIK: 1145197
| Field | Detail |
|---|---|
| Company | Insulet Corp (PODD) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $170 million, $282 million, $452 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, routine-disclosure
TL;DR
Insulet filed a routine 8-K, no major news.
AI Summary
On December 3, 2024, Insulet Corporation filed an 8-K report to disclose other events and financial statements/exhibits. The filing does not contain specific details about material events or financial performance beyond its routine nature.
Why It Matters
This 8-K filing by Insulet Corporation is a routine disclosure, indicating no significant new events or financial information requiring immediate attention.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for 'Other Events' and 'Financial Statements and Exhibits' with no specific material events disclosed.
Key Players & Entities
- INSULET CORP (company) — Registrant
- December 3, 2024 (date) — Date of earliest event reported
- 100 Nagog Park Acton Massachusetts 01720 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Insulet Corporation?
The primary purpose of this 8-K filing is to report 'Other Events' and to include 'Financial Statements and Exhibits' as of December 3, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is December 3, 2024.
What is Insulet Corporation's principal executive office address?
Insulet Corporation's principal executive office is located at 100 Nagog Park Acton, Massachusetts 01720.
What is the SIC code for Insulet Corporation?
The Standard Industrial Classification (SIC) code for Insulet Corporation is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
Is this filing intended to satisfy any specific provisions beyond current reporting requirements?
The filing explicitly states that it is not intended to simultaneously satisfy the filing obligation under any of the other provisions listed in General Instruction A.2.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-12-04 16:34:40
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value Per Share PODD The NASDAQ St
- $170 million — e secrets. The jury awarded the Company $170 million in compensatory damages from EOFlow and
- $282 million — y damages from EOFlow and an additional $282 million in exemplary damages from EOFlow for wi
- $452 million — opriation, for a total damages award of $452 million. EOFlow's ability to satisfy this damag
Filing Documents
- podd-20241203.htm (8-K) — 33KB
- podd-2024x12x04ex991.htm (EX-99.1) — 8KB
- 0001145197-24-000048.txt ( ) — 164KB
- podd-20241203.xsd (EX-101.SCH) — 2KB
- podd-20241203_lab.xml (EX-101.LAB) — 21KB
- podd-20241203_pre.xml (EX-101.PRE) — 12KB
- podd-20241203_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On December 4, 2024, Insulet Corporation (the "Company") issued a press release announcing that, on December 3, 2024, after a four-week trial in the U.S. District Court for the District of Massachusetts in the manner of Insulet Corporation vs. EOFlow Co., Ltd. et al., a jury verdict was returned in favor of the Company. The jury found that EOFlow Co., Ltd. ("EOFlow") and several other defendants misappropriated certain of the Company's trade secrets. The jury awarded the Company $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages from EOFlow for willful and malicious misappropriation, for a total damages award of $452 million. EOFlow's ability to satisfy this damage award is not known with certainty. EOFlow and other defendants may seek to appeal the verdict. The Company intends to seek injunctive relief from the court in addition to the monetary damages awarded by the jury.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibit is filed as part of this report: No. Exhibit 99.1 Press Release dated December 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned thereunto duly authorized. INSULET CORPORATION December 4, 2024 By: /s/ John W. Kapples Name: John W. Kapples Title: Senior Vice President, General Counsel